The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. In a phase III trial in patients...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Tzogani, Kyriaki, Camarero Jiménez, Jorge, Garcia, Isabel, Sancho‐López, Arantxa, Martin, Marc, Moreau, Alexandre, Demolis, Pierre, Salmonson, Tomas, Bergh, Jonas, Laane, Edward, Ludwig, Heinz, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2017
Assuntos:
Regulatory Issues: EMA
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679835/
https://ncbi.nlm.nih.gov/pubmed/28935772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0184
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares